CY1106169T1 - Συνθεση αποτελουμενη απο προπιονυλ l-καρνιτινη και γλυκινη για την προληψη και/ή θepαπεια των κυτοτοξικων αποτελεσματων που διεγειρονται απο τη χρηση ανοσοκατασταλτικων παραγοντων - Google Patents
Συνθεση αποτελουμενη απο προπιονυλ l-καρνιτινη και γλυκινη για την προληψη και/ή θepαπεια των κυτοτοξικων αποτελεσματων που διεγειρονται απο τη χρηση ανοσοκατασταλτικων παραγοντωνInfo
- Publication number
- CY1106169T1 CY1106169T1 CY20061101374T CY061101374T CY1106169T1 CY 1106169 T1 CY1106169 T1 CY 1106169T1 CY 20061101374 T CY20061101374 T CY 20061101374T CY 061101374 T CY061101374 T CY 061101374T CY 1106169 T1 CY1106169 T1 CY 1106169T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carnitine
- propionyl
- glycine
- prevention
- treatment
- Prior art date
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000004471 Glycine Substances 0.000 title abstract 2
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical group CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Αποκαλύπτεται σύνθεση η οποία είναι κατάλληλη για την πρόληψη ή και θεραπεία ανωμαλιών κυττάρου και ιστού, εξωγενούς, τοξικής ή μεταβολικής προέλευσης και κατάλληλη για μείωση των τοξικών αποτελεσμάτων κυκλοσπορίνης-Α και άλλων ανοσοκατασταλτικών παραγόντων που μπορεί να πάρει τη μορφή ενός συμπληρώματος τροφής ή ενός πραγματικού φαρμάκου, που περιέχει σαν τα δραστικά συστατικά αυτής σε συνδυασμό ή ξεχωριστά συσκευασμένα : (α) προπιονύλ L-καρνιτίνη ή ένα των φαρμακολογικώς αποδεκτών αλάτων αυτής και (β) ένα αμινοξύ που επιλέγεται από την ομάδα που αποτελείται από γλυκίνη, σερίνη, αλανίνη και αργινίνη ή μίγματα αυτών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000RM000107A IT1316998B1 (it) | 2000-03-02 | 2000-03-02 | Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori. |
| PCT/IT2001/000082 WO2001064204A2 (en) | 2000-03-02 | 2001-02-20 | Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106169T1 true CY1106169T1 (el) | 2011-06-08 |
Family
ID=11454493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101374T CY1106169T1 (el) | 2000-03-02 | 2006-09-25 | Συνθεση αποτελουμενη απο προπιονυλ l-καρνιτινη και γλυκινη για την προληψη και/ή θepαπεια των κυτοτοξικων αποτελεσματων που διεγειρονται απο τη χρηση ανοσοκατασταλτικων παραγοντων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7897641B2 (el) |
| EP (1) | EP1267863B1 (el) |
| AR (1) | AR027963A1 (el) |
| AT (1) | ATE335476T1 (el) |
| AU (2) | AU2001241031B8 (el) |
| CA (1) | CA2400728C (el) |
| CY (1) | CY1106169T1 (el) |
| CZ (1) | CZ20022759A3 (el) |
| DE (1) | DE60122120T2 (el) |
| DK (1) | DK1267863T3 (el) |
| ES (1) | ES2269356T3 (el) |
| HU (1) | HUP0300083A3 (el) |
| IT (1) | IT1316998B1 (el) |
| MX (1) | MXPA02008531A (el) |
| PL (1) | PL202682B1 (el) |
| PT (1) | PT1267863E (el) |
| SK (1) | SK11892002A3 (el) |
| TN (1) | TNSN01032A1 (el) |
| WO (1) | WO2001064204A2 (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6775419B2 (ja) * | 2014-04-22 | 2020-10-28 | 味の素株式会社 | 末梢神経障害の予防又は改善用組成物 |
| CN115469026B (zh) * | 2022-07-14 | 2023-10-20 | 中日友好医院(中日友好临床医学研究所) | 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| US5290538A (en) * | 1988-12-22 | 1994-03-01 | Skrezek Christian | Nephro protective infusion solutions |
| JPH0662547B2 (ja) * | 1989-01-10 | 1994-08-17 | 田辺製薬株式会社 | グリシン誘導体 |
| IT1248323B (it) * | 1991-05-16 | 1995-01-05 | Sigma Tau Ind Farmaceuti | Ammidi con amminoacidi naturali di alcanoil l-carnitine quali inibitori della degenerazione neuronale e attivatori dei processi di apprendimento e memorizzazione e per il trattamento del coma e composizioni farmaceutiche comprendenti tali composti |
| IT1245869B (it) | 1991-06-05 | 1994-10-25 | Sigma Tau Ind Farmaceuti | Impiego di propionil l-carnitina per il recupero del tono muscolare in soggetti immobilizzati |
| US5763408A (en) * | 1992-06-03 | 1998-06-09 | Fuji Photo Film Co., Ltd. | Amino acid derivatives and application thereof |
| US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| IT1277147B1 (it) * | 1995-01-20 | 1997-11-04 | Sigma Tau Ind Farmaceuti | Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi. |
| DK0793962T3 (da) * | 1996-03-04 | 2000-05-22 | Sigma Tau Ind Farmaceuti | Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans |
| US6348495B1 (en) * | 1996-06-06 | 2002-02-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Method for treating celiac disease |
| IT1291113B1 (it) * | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| IT1291127B1 (it) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
| IT1302863B1 (it) | 1998-11-13 | 2000-10-10 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un |
| IT1306130B1 (it) * | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
| IT1306173B1 (it) * | 1999-07-23 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare. |
| IT1306722B1 (it) * | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
| IT1307278B1 (it) * | 1999-11-18 | 2001-10-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil |
| IT1317062B1 (it) * | 2000-07-14 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore alimentare utile per prevenire le disfunzioni epatiche ebiliari comprendente una alcanoil l-carnitina. |
| ITRM20010155A1 (it) * | 2001-03-23 | 2002-09-23 | Biosalts Srl | Sale di creatina ad aumentato valore nutrizionale e terapeutico e composizioni che lo contengono. |
-
2000
- 2000-03-02 IT IT2000RM000107A patent/IT1316998B1/it active
-
2001
- 2001-02-20 ES ES01912114T patent/ES2269356T3/es not_active Expired - Lifetime
- 2001-02-20 CZ CZ20022759A patent/CZ20022759A3/cs unknown
- 2001-02-20 HU HU0300083A patent/HUP0300083A3/hu unknown
- 2001-02-20 CA CA002400728A patent/CA2400728C/en not_active Expired - Fee Related
- 2001-02-20 PT PT01912114T patent/PT1267863E/pt unknown
- 2001-02-20 PL PL358267A patent/PL202682B1/pl unknown
- 2001-02-20 AT AT01912114T patent/ATE335476T1/de active
- 2001-02-20 EP EP01912114A patent/EP1267863B1/en not_active Expired - Lifetime
- 2001-02-20 DE DE60122120T patent/DE60122120T2/de not_active Expired - Lifetime
- 2001-02-20 MX MXPA02008531A patent/MXPA02008531A/es active IP Right Grant
- 2001-02-20 SK SK1189-2002A patent/SK11892002A3/sk unknown
- 2001-02-20 WO PCT/IT2001/000082 patent/WO2001064204A2/en active IP Right Grant
- 2001-02-20 AU AU2001241031A patent/AU2001241031B8/en not_active Ceased
- 2001-02-20 US US10/220,185 patent/US7897641B2/en not_active Expired - Fee Related
- 2001-02-20 AU AU4103101A patent/AU4103101A/xx active Pending
- 2001-02-20 DK DK01912114T patent/DK1267863T3/da active
- 2001-02-27 TN TNTNSN01032A patent/TNSN01032A1/fr unknown
- 2001-02-27 AR ARP010100885A patent/AR027963A1/es unknown
-
2006
- 2006-09-25 CY CY20061101374T patent/CY1106169T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1267863T3 (da) | 2006-12-04 |
| ATE335476T1 (de) | 2006-09-15 |
| US20030144354A1 (en) | 2003-07-31 |
| US7897641B2 (en) | 2011-03-01 |
| IT1316998B1 (it) | 2003-05-26 |
| HUP0300083A2 (hu) | 2003-06-28 |
| ITRM20000107A1 (it) | 2001-09-02 |
| DE60122120T2 (de) | 2007-02-08 |
| CZ20022759A3 (cs) | 2003-02-12 |
| AU2001241031B8 (en) | 2005-12-01 |
| ES2269356T3 (es) | 2007-04-01 |
| AR027963A1 (es) | 2003-04-16 |
| EP1267863A2 (en) | 2003-01-02 |
| WO2001064204A2 (en) | 2001-09-07 |
| TNSN01032A1 (fr) | 2005-11-10 |
| PT1267863E (pt) | 2006-10-31 |
| PL202682B1 (pl) | 2009-07-31 |
| HUP0300083A3 (en) | 2004-07-28 |
| AU4103101A (en) | 2001-09-12 |
| AU2001241031B2 (en) | 2005-10-27 |
| PL358267A1 (en) | 2004-08-09 |
| SK11892002A3 (sk) | 2003-02-04 |
| MXPA02008531A (es) | 2003-02-12 |
| CA2400728C (en) | 2009-04-28 |
| DE60122120D1 (de) | 2006-09-21 |
| CA2400728A1 (en) | 2001-09-07 |
| EP1267863B1 (en) | 2006-08-09 |
| WO2001064204A3 (en) | 2002-03-28 |
| ITRM20000107A0 (it) | 2000-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE218582T1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen | |
| ATE218580T1 (de) | Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen | |
| PE20110236A1 (es) | Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina | |
| RU2011115418A (ru) | Усиление действия противораковых агентов | |
| ES2103857T3 (es) | Peptidos ciclicos y su uso. | |
| ATE311227T1 (de) | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne | |
| CY1111698T1 (el) | Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης | |
| TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
| CY1115918T1 (el) | Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη | |
| TR199802534T2 (xx) | Leptin (OB Protein) fragmanlar� | |
| RU2007129266A (ru) | Фармацевтический состав для профилактики рака и для борьбы с ним | |
| FR2846883B1 (fr) | Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide | |
| CY1106169T1 (el) | Συνθεση αποτελουμενη απο προπιονυλ l-καρνιτινη και γλυκινη για την προληψη και/ή θepαπεια των κυτοτοξικων αποτελεσματων που διεγειρονται απο τη χρηση ανοσοκατασταλτικων παραγοντων | |
| IT1276162B1 (it) | Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche | |
| IL131216A (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
| ATE505199T1 (de) | Pharmazeutische, kosmetische oder therapeutische zusammensetzungen enthaltend peptide mit dem motiv arg-gly-ser | |
| TR200103151T2 (tr) | Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon. | |
| SE0103528D0 (sv) | Topiska kompositioner med förstärkt effekt | |
| MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
| GB9505082D0 (en) | Medicament | |
| DK1189615T3 (da) | Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner | |
| CO5611158A2 (es) | Metodos y composiciones para tratar toxicidad gastrointestinal inducida por terapia citoablativa | |
| SE9904132D0 (sv) | Pharmaceutical composition for treatment of diarrhea | |
| AR008764A1 (es) | Sales hidratadas de n,n'-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo. | |
| SE0002232D0 (sv) | Antioxidant |